Table 2. The distribution of reverse transcriptase (RT) mutations and HBsAg vaccine escape mutations among the study population.

Sample ID	Age	Gender	Year of Dx1	Sub-genotype	Rx status2	Mutations RT3	Escape mutations
22	38	Male	2009	D1	Naïve	N53S, F122I, H124D, Y135S, H216L, L217F	–
39	35	Male	2009	D1	Unknown	Y135S, H216L, L217F	–
84	35	Male	Unknown	D1	Unknown	F122I, H124Y, Y135S, H216L, L217F	–
97	36	Male	1995	D1	Naïve	R110G, Y135S, H216L	–
23	68	Male	2009	D1	Unknown	F122I, H124Y, Y135S, H216L	–
66	38	Male	2004	D1	Unknown	H124Y, Y135S, I163V, H216I, L217F	–
85	33	Female	2004	D1	Naïve	S119P, H124Y, Y135S, H216L	–
99	33	Male	2007	D1	Experienced (Lamivudine)	F122I, H124Y, Y135S, L217F	–
4	30	Male	2006	D1	Naïve	L91I, H124Y, N131D, Y135S, H216L, L217F	–
24	22	Female	2009	D1	Experienced (Lamivudine)	Y135S, H216I, L217F	–
45	38	Female	1998	D1	Experienced (Lamivudine)	H124Y, Y135S, Q215H, H216L	–
101	30	Male	2010	D1	Unknown	F122I, H124Y, Y135S, H216L, L217F	–
2	60	Male	2009	D1	Experienced (Lamivudine)	Y135S, H216L, L217F	R122K
46	35	Female	2000	D1	Experienced (Lamivudine)	H124Y, Y135S, Q215H, H216F, L217W	–
57	39	Female	2010	D1	Unknown	A38E, Y54H, M129L, Y135S, V173L, H216L	–
87	30	Male	2011	D1	Unknown	K32M, Y135S, S213T, H216I	–
106	47	Male	2011	D1	Unknown	F122I, H124Y, Y135S, H216L	–
6	13	Male	2009	D1	Experienced (Lamivudine)	H124Y, Y135S, Q149K, H216L	–
49	32	Female	2008	D1	Unknown	S85A, Y135S, N139D, L199V, H216I, L217W	L109R
76	51	Female	2009	D1	Naïve	L91I, H124D, Y135S, K212N, H216P	S143L
81	38	Male	1998	D1	Experienced (Lamivudine)	S78T, F122I, H124Y, Y135S, H216I	–
83	51	Male	2000	D1	Unknown	A38E, R110G, F122I, H124Y, Y135S, Q149K, S176T, S185I, H197P, C198R, S202I, V208I, A211G, K212G, S213Q, V214Y, Q215L, H216L, L217F	–
5	11	Male	2009	D1	Experienced (Lamivudine)	Y135S, H216L, L217F	–
34	26	Male	2008	D1	Unknown	F122I, H124Y, Y135S, H216L	–
52	25	Male	2009	D1	Naïve	H124Y, Y135S, H216P	–
70	44	Male	2011	D1	Naïve	Y54G, N76D, Y135S, Y141F, H216I, L217F	M133L
89	24	Male	2009	D1	Unknown	Y54H, Y135S, H216L	D144E
105	48	Female	2011	D1	Naïve	H124Y, T128P, Y135S, L145M, H216P	–
8	60	Male	1984	D1	Experienced (Lamivudine)	A38E, Y54H, H124Y, M129L, Y135S, V173L, L180M, M204V, H216L	–
35	29	Male	2009	D1	Unknown	S109P, Y135S, H216L, L217F	–
56	36	Male	2010	D1	Unknown	T37A, F122L, N123D, Y135S, H216L	–
77	65	Male	2011	D1	Naïve	H124Y, Y135S, G152K, K154N, I187L, H216P, L217F	–
103	23	Female	2011	D1	Naïve	N53K, F122I, H124Y, Y135S, H216L	–
63	77	Male	2004	D1	Unknown	H124Y, Y135S, Q215H, H216T, L217F	R122K
38	34	Female	2007	D1	Unknown	F122I, H124Y, Y135S, H216I, L217W	–
58	65	Female	2006	D1	Unknown	V27A, A38E, S117N, N118D, H124D, Y135S, S137T, L180M, M204V, H216L	R122K, Q129R
104	37	Male	2007	D1	Experienced (Lamivudine)	A38E, H124Y, Y135S, L180M, T184A, M204V, H216I	–

Notes:

RT mutation conferring possible or confirmed resistance to RT inhibitors are highlighted in bold.

¹Dx, diagnosis.

²Rx, treatment.

³RT, reverse transcriptase.